Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Other Non-Current Liabilities (2017 - 2025)

Historic Other Non-Current Liabilities for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to $2.0 million.

  • Seres Therapeutics' Other Non-Current Liabilities rose 1295.57% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 1295.57%. This contributed to the annual value of $1.8 million for FY2024, which is 1289.93% up from last year.
  • Per Seres Therapeutics' latest filing, its Other Non-Current Liabilities stood at $2.0 million for Q3 2025, which was up 1295.57% from $2.0 million recorded in Q2 2025.
  • Seres Therapeutics' Other Non-Current Liabilities' 5-year high stood at $11.5 million during Q4 2021, with a 5-year trough of $777000.0 in Q1 2021.
  • In the last 5 years, Seres Therapeutics' Other Non-Current Liabilities had a median value of $1.7 million in 2024 and averaged $2.5 million.
  • In the last 5 years, Seres Therapeutics' Other Non-Current Liabilities skyrocketed by 104606.18% in 2021 and then tumbled by 8828.48% in 2022.
  • Over the past 5 years, Seres Therapeutics' Other Non-Current Liabilities (Quarter) stood at $11.5 million in 2021, then crashed by 87.46% to $1.4 million in 2022, then rose by 12.9% to $1.6 million in 2023, then grew by 12.9% to $1.8 million in 2024, then increased by 9.58% to $2.0 million in 2025.
  • Its Other Non-Current Liabilities stands at $2.0 million for Q3 2025, versus $2.0 million for Q2 2025 and $1.9 million for Q1 2025.